MEDAPP S.A. ZY -10 Cash Flow Conversion Efficiency
MEDAPP S.A. ZY -10 cash flow conversion efficiency. Based on the latest financial reports, MEDAPP S.A. ZY -10 (WQ1) has a cash flow conversion efficiency ratio of 0.076x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.04 Million ≈ $2.39 Million USD) by net assets (€26.82 Million ≈ $31.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see WQ1 stock market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of MEDAPP S.A. ZY -10 (2021–2025)
Cash flow conversion efficiency of MEDAPP S.A. ZY -10 from 2021 to 2025. This chart illustrates how MEDAPP S.A. ZY -10's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest MEDAPP S.A. ZY -10 stock price today for real-time trading data and today's change.
MEDAPP S.A. ZY -10 Cash Flow Conversion Ratio Explained
MEDAPP S.A. ZY -10 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MEDAPP S.A. ZY -10 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MEDAPP S.A. ZY -10 ranked by their cash flow conversion efficiency. Review how much free cash does MEDAPP S.A. ZY -10 generate to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Starhedge SA
WAR:SHG
|
-0.004x |
|
SKAKO A/S
CO:SKAKO
|
0.066x |
|
XWELL Inc.
NASDAQ:XWEL
|
0.003x |
|
GR BUSSINES SO
F:INW
|
N/A |
|
Jatcorp Ltd
AU:JAT
|
0.335x |
|
ARIP Public Company Limited
BK:ARIP
|
0.160x |
|
Farlim Group (Malaysia) Bhd
KLSE:6041
|
-0.019x |
|
Battery Age Minerals Ltd
AU:BM8
|
-0.053x |
Annual Cash Flow Conversion Efficiency for MEDAPP S.A. ZY -10 (2021–2025)
The table below shows the annual cash flow conversion efficiency of MEDAPP S.A. ZY -10 from 2021 to 2025. Also see WQ1 total asset value for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €26.82 Million ≈ $31.35 Million |
€2.44 Million ≈ $2.85 Million |
0.091x | -37.13% |
| 2024-12-31 | €28.84 Million ≈ $33.71 Million |
€4.17 Million ≈ $4.87 Million |
0.144x | +391.16% |
| 2023-12-31 | €26.73 Million ≈ $31.25 Million |
€-1.33 Million ≈ $-1.55 Million |
-0.050x | -123.57% |
| 2022-12-31 | €27.19 Million ≈ $31.79 Million |
€5.72 Million ≈ $6.69 Million |
0.210x | +1315.77% |
| 2021-12-31 | €25.25 Million ≈ $29.52 Million |
€-437.00K ≈ $-510.90K |
-0.017x | -- |
About MEDAPP S.A. ZY -10
MedApp S.A. engages in the development of solutions to support imaging diagnostics and digital medicine in Poland, rest of the European Union, and internationally. The company offers CarnaLife Holo, a technology for 3D visualization of imaged medical data which supports the planning and performance of medical procedures. HoloComm, an innovative solution for easy and convenient work on files in 3D… Read more